The Bull Rankings scorecard — our quality-growth score is 73.8 / 100, built from three pillars scored 0–100: Quality 97, Growth 80, Value 52 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 2% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Exelixis is a high‑quality growth business whose price assumes little growth. Our model gives it a 73.8/100 quality‑growth score, with Quality 97, Growth 80, and Value 52. The story is driven by the Quality pillar: a profit margin of 35.3% and a ROE of 46.7%. Those margins translate into a free‑cash‑flow of $1.2 b in the trailing twelve months, a figure that supports the current $56.21 price without demanding an aggressive earnings multiple. The PE of 17.7 and a PEG of 2.56 say analysts expect earnings growth a bit below the 9.2% revenue growth YoY. In short, the stock is a solid, cash‑generating oncology drugmaker that is not begging for a price hike.
What the business actually is
Exelixis develops and sells targeted oncology therapies in the United States. Its flagship product, CABOMETYX, treats advanced renal cell carcinoma after anti‑angiogenic therapy. COMETRIQ addresses metastatic medullary thyroid cancer, and both are formulations of cabozantinib, a multi‑kinase inhibitor that blocks MET, AXL, RET, and VEGF receptors. Exelixis also earns royalties on COTELLIC, a MEK inhibitor sold by Genentech for certain melanomas, and MINNEBRO, a hypertension drug sold by Daiichi Sankyo in Japan. The revenue engine is therefore a small, high‑margin cabozantinib franchise that commands premium pricing.
Why it can (or can't) keep compounding
The durability case hinges on Exelixis’s low debt‑to‑equity of 0.09 and a beta of 0.42, indicating a stable, low‑risk profile in a volatile sector. The company’s Durable high returns signal from our model underscores that the cash‑flow generation is not a one‑off event. CABOMETYX and COMETRIQ enjoy strong patent protection and a high barrier to entry: competitors would need to replicate a complex kinase inhibition profile and secure regulatory approval, a process that takes years and significant capital. The Buying back stock signal further tightens the equity base, boosting earnings per share and protecting shareholder value. With a ROE of 46.7%, the firm is already compounding capital efficiently; any incremental growth will be amplified by the existing cash‑flow engine.
The valuation question
The current $56.21 price implies a reverse‑DCF growth of roughly –2% per year in free‑cash‑flow (in year one, recovering toward 3% a year by year ten). That figure sits well below the 9.2% revenue growth YoY, meaning the market is already pricing in a modest slowdown in cash‑flow expansion. The PE of 17.7 is modest for a biotech, but the PEG of 2.56 indicates analysts expect earnings to grow slightly slower than revenue. In other words, pessimism is already baked into the price: the implied cash‑flow growth is lower than revenue growth, so the stock is not demanding a premium for future expansion. If revenue growth were to accelerate beyond 9.2%, the current valuation would look attractive; if it stalls, the price will likely compress.
The bear case
The weakest pillar in our model is Value 52, only slightly on the cheap side, suggesting the stock is not a deep bargain. The PEG of 2.56 is high, implying the price leans on growth expectations more than on recent performance. A concrete trigger for the bear case would be a decline in revenue growth below 9.2% or a margin squeeze below 35.3%. Such a shift would invalidate the implied cash‑flow growth assumption and erode the case for upside.
What would change our mind
- Revenue growth falling under 9.2% would suggest the market’s caution is warranted.
- Profit margin dipping below 35.3% would signal cost pressures or pricing erosion, weakening the cash‑flow narrative.
- A significant drop in the Quality pillar—for example, a ROE falling below 40%—would erode the confidence that the company can sustain its high returns.
If any of these thresholds are breached, the current upside would evaporate, and the stock would move from a quality growth play to a speculative one.